Cholangiocarcinoma News and Research

RSS

Tuft cell-like cancers exhibit unique biological characteristics across multiple organs

A growing body of evidence suggests that a rare epithelial cell type known as the tuft cell may play a far more significant role in cancer than previously recognized.

6 Aug 2026

Targeted therapy doubles progression-free survival in rare bile duct cancer

Results of the ongoing eNRGy trial, a single-arm, multicenter, global phase 2 clinical trial evaluating zenocutuzumab in solid tumors positive for Neuregulin 1 (NRG1) gene fusions, reported manageable side effects and clinically meaningful efficacy – including a near doubling of progression-free survival compared to expectations with standard of care – in previously treated patients with advanced NRG1-positive cholangiocarcinoma.

2 Jul 2026

New AI framework outperforms conventional biomarkers in predicting cancer survival

Digestive system cancers, including hepatobiliary and gastrointestinal malignancies, remain a major global oncological burden. Although immune checkpoint inhibitors have changed the treatment landscape for some patients, their overall efficacy remains limited, with only about 15% to 30% of patients achieving durable clinical benefit.

1 Jul 2026

Trial shows safety of novel KIR-CAR T therapy in solid tumors

An innovative type of CAR T cell therapy, called KIR-CAR, was shown to be safe, with increasing efficacy corresponding to higher doses of the investigational treatment in nine patients with advanced ovarian cancer, mesothelioma or cholangiocarcinoma (bile duct cancer), according to an early report from an ongoing Phase I dose-escalation clinical trial.

20 Apr 2026

New roadmap links liver cancer biology to immunotherapy and precision medicine

A new review from the Icahn School of Medicine at Mount Sinai and the Hospital Clínic de Barcelona provides one of the clearest roadmaps to date for understanding and treating liver cancer, one of the deadliest cancers worldwide.

17 Apr 2026

High-dose radiation improves survival in large bile duct tumors

A new study from researchers at The University of Texas MD Anderson Cancer Center demonstrates that a specialized high-dose type of radiation delivery may significantly improve outcomes for patients with large bile duct tumors in the liver, known as intrahepatic cholangiocarcinoma.

2 Apr 2026

Gene signature maps cholangiocarcinoma subtypes for precision treatment

Intrahepatic cholangiocarcinoma (iCCA), the second most common primary liver cancer after hepatocellular carcinoma, remains one of the most challenging malignancies to treat due to its highly concealed and heterogeneous nature.

31 Mar 2026

New genetic ‘roadmap’ advances precision therapy for intrahepatic cholangiocarcinoma

The 1,341-gene signature for intrahepatic cholangiocarcinoma offers a framework for precise diagnosis and tailored therapies, addressing tumor heterogeneity.

From BGI Genomics 31 Mar 2026

Experts call for rapid improvements in diagnosis, treatment of bile duct cancer

The international group of experts, including Professor John Bridgewater (UCL Cancer Institute), is calling for rapid improvements in diagnosis, treatment and research for cholangiocarcinoma, also known as bile duct cancer.

2 Mar 2026

Diagnostic prognostic and therapeutic relevance of PIVKA-II in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, particularly in regions with high hepatitis B virus prevalence.

24 Jan 2026

Blood test identifies colon cancer patients who benefit from anti-inflammatory medication

A blood test could help doctors decide which patients with colon cancer should receive anti-inflammatory medication along with chemotherapy after surgery, according to new study in JAMA Oncology.

15 Dec 2025

FOLFIRINOX shows promise as a second-line option for advanced biliary tract cancer

Biliary tract cancers, including intrahepatic, perihilar, and extrahepatic cholangiocarcinoma and gallbladder cancer, are among the most aggressive gastrointestinal malignancies.

27 Nov 2025

After series of denials, his insurer approved doctor-recommended cancer care. It was too late.

For nearly three years, Eric Tennant endured chemotherapy infusions, rounds of radiation, biopsies, and hospitalizations that left him weak and depleted.

21 Nov 2025

E2F2 protein identified as potential therapeutic target to prevent metabolic fatty liver disease progression

An international collaborative study has identified the E2F2 protein as a potential new therapeutic target to prevent metabolic fatty liver disease from progressing towards more serious conditions, such as cirrhosis or liver cancer.

22 Oct 2025

New method uncovers how extracellular vesicles impact immune response in cancer

Certain types of biochemical processes can impair the immune system's ability to recognize and kill cancer cells. Purdue University's W. Andy Tao and his associates have developed a new way to study these processes.

26 Aug 2025

International commission calls for action against hepatocellular carcinoma

Liver cancer is the sixth most common cancer as well as the third highest cause of cancer-related mortality worldwide.

8 Aug 2025

Rising liver cancer rates highlight need for urgent action worldwide

The majority of liver cancer cases could be prevented by reducing levels of viral hepatitis, alcohol consumption and MASLD (metabolic dysfunction-associated steatotic liver disease – previously called non-alcoholic fatty liver disease), suggests an analysis as part of The Lancet Commission on liver cancer.

29 Jul 2025

Combination therapy sets new survival standard for advanced biliary tract cancer

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an immunotherapy drug) plus gemcitabine and cisplatin (GemCis, chemotherapy drugs) as the first-line treatment for people with advanced biliary tract cancer (aBTC), researchers have shown that after three years more than twice as many study participants treated with durvalumab plus GemCis had survived compared to those treated with a placebo plus GemCis.

10 Jul 2025

Innovative approach for the development of next-generation cancer therapies targeting FGFR2/3

Aberrations in fibroblast growth factor receptors FGFR2/3 are major drivers of many cancers-including intrahepatic cholangiocarcinoma, endometrial, breast, gastric, and bladder cancers.

4 Jul 2025

Advancing precision oncology in intrahepatic cholangiocarcinoma

ICCA accounts for 10–15% of primary liver cancers and is notorious for late-stage diagnosis and resistance to chemotherapy and radiotherapy.

13 Jun 2025